News - MedTech & Diagnostics
Innovative method to regenerate articular cartilage for patient surgery

MedTech News: Recipient of the Royal Australasian College of Surgeons (RACS) Senior Lecturer Fellowship, Associate Professor Claudia Di Bella, and her research team at BioFab3D, trademarked a ground-breaking method of stem cell transplantation.
BioFab3D is Australia’s first robotics and biomedical engineering centre within a hospital. Researchers, clinicians, engineers and industry partners work to build biological structures such as cartilage, muscle, bone, nerves and organs – almost anything that requires repair through disease and physical trauma.
St Vincent’s Hospital Melbourne has partnered with four universities – the University of Melbourne, RMIT University, Swinburne University of Technology and University of Wollongong – to create a unique hub for
innovation and translation.
Associate Professor Di Bella’s team is regenerating articular cartilage by using advanced biofabrication techniques and technology with the use of stem cells that are printed within a gelatinous scaffold and then cultured in 3D. The cartilage project is the largest program at BioFab3D.
The typical pathway for a stem cell transplant procedure involves taking
cells from the patient, then printing and growing them in the lab while the patient waits at home for the cells to do their work and create tissue. The third and final stage is reimplantation into the patient.
The BioFab3D team is hoping to eliminate the second stage of this process because it’s a big obstacle to Therapeutic Goods Administration (TGA) approval, or to any process that involves tissue engineering.
The revolutionary new procedure that the team hopes to implement will require one simple step. It will take the patient’s own stem cells, then mix them with a scaffold so they have somewhere to grow before putting them back into the same patient to regenerate their own cartilage.
The product has been trademarked, registered and seeking a pathway towards commercialisation. A clinical trial will also commence shortly.
Leadership & Management
David Henderson appointed Takeda Oceania Country Head
David Henderson has been appointed Country Head for Takeda Oceania, succeeding Dave Pearce, as the pharmaceutical company continues to reshape […]
MoreNews - Pharmaceuticals
GBMA puts medicine shortages on the table as strategic agreement talks begin
As the Generic and Biosimilar Medicines Association (GBMA) begins negotiations with government on the next strategic agreement, it has unveiled […]
MoreNews - MedTech & Diagnostics
Australia sets a new course for prostate cancer detection
Australia has become one of the first countries in the world to adopt a modern, evidence-based framework for the early […]
MoreNews - Pharmaceuticals
IVF success rates climb as ART sector faces major accreditation overhaul
Australians undergoing in vitro fertilisation (IVF) are now more likely to take home a baby than they were five years […]
More